
DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
A survey recently completed by the industry revealed that the time it takes companies to design and release clinical study databases is having a negative impact on the completion of trials. The delays around the database lead to increased time for other data management processes which ultimately contributes to the slowing of study completion all together.
Read the full release






